Why the study?
Doxorubicin is widely used against cancer but carries the risk of progressive cardiomyopathy associated with mitochondrial loss.
p53 plays a protective role against doxorubicin-induced cardiomyopathy by regulating mitochondrial DNA transcription and maintenance, independent of its cell death pathways.
Doxorubicin is widely used against cancer but carries the risk of a progressive cardiomyopathy associated with mitochondrial loss. Using genetic models, our recent study demonstrates that mitochondrial genomic DNA regulation by tumor protein p53 (TP53, best known as p53) prevents the cardiotoxicity of low dose doxorubicin which does not activate the p53-dependent cell death pathway.
No takes yet. Share an insight, caveat, or question.
Nishi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: